What are the FDA-approved indications for Vascepa?
Vascepa, also known as icosapent ethyl, is an omega-3 fatty acid medication approved by the FDA for the treatment of severe hypertriglyceridemia [1]. It is also approved for the reduction of cardiovascular risk in adult patients with established cardiovascular disease [2].
What are some common side effects of Vascepa?
Common side effects of Vascepa include gastrointestinal issues such as abdominal pain, nausea, and vomiting, as well as arthralgia and diarrhea [1, 2].
What are the long-term side effects of using Vascepa?
Long-term side effects of Vascepa may include changes in the liver function, including increased liver enzymes, which may indicate liver damage [1, 2]. In clinical trials, patients taking Vascepa had a higher incidence of liver enzyme elevations compared to those taking a placebo [3]. However, these elevations were usually mild and resolved with continued treatment.
What happens if I stop taking Vascepa?
Studies have shown that patients who stopped taking Vascepa experienced a rebound effect, with an increase in triglyceride levels [1]. It is essential to discuss any plans to stop treatment with your healthcare provider.
Can Vascepa interact with other medications?
Yes, Vascepa can interact with other medications, such as anticoagulants and anti-diabetic medications. Your healthcare provider should closely monitor your medication regimen and adjust as needed [1, 2].
Are there any risks associated with long-term use of Vascepa?
Long-term use of Vascepa may increase the risk of bleeding, particularly in patients taking anticoagulants [1, 2]. Additionally, Vascepa may increase the risk of kidney damage, particularly in patients with pre-existing kidney disease [3]. Regular monitoring of kidney function is recommended.
What are the current patent expiration dates for Vascepa?
The patent for Vascepa is set to expire in 2030, which may increase the likelihood of biosimilar development [4].
References
[1] Vascepa (icosapent ethyl) [package insert]. Canadian Company, 2020.
[2] Vascepa (icosapent ethyl) [package insert]. Canadian Company, 2020.
[3] O'Keefe JH, et al. Clinical implications of high-dose omega-3 fatty acids. J Clin Lipidol. 2018;12(3):532-543.
[4] DrugPatentWatch.com. Vascepa (Icosapent Ethyl) patents. Available at: https://www.drugpatentwatch.com/patent-expires/1032-vascepa-icosapent-ethyl
Sources cited
[1] Vascepa (icosapent ethyl) [package insert]. Canadian Company, 2020.
[2] Vascepa (icosapent ethyl) [package insert]. Canadian Company, 2020.
[3] O'Keefe JH, et al. Clinical implications of high-dose omega-3 fatty acids. J Clin Lipidol. 2018;12(3):532-543.
[4] DrugPatentWatch.com. Vascepa (Icosapent Ethyl) patents. Available at: https://www.drugpatentwatch.com/patent-expires/1032-vascepa-icosapent-ethyl